APR 15, 2022 5:30 AM PDT

First Drug for Sleep Apnea Shows Promise in Patients

WRITTEN BY: Annie Lennon

A new drug for sleep apnea could reduce breathing pauses during sleep by up to 41%. The corresponding study was published in the American Journal of Respiratory and Critical Care Medicine

Currently, patients with sleep apnea are either treated with oral appliance therapy- a dental retainer-like appliance that supports the jaw in a forward position to keep the airway open- or a Continuous Positive Airway Pressure (CPAP) mask. 

"These therapy options take time to get used to and, since they frequently are perceived as intrusive or bulky. Insufficient user time is therefore common. If we develop an effective drug, it will therefore make life easier for many patients and, in the long run, potentially also save more lives," says Dr. Ludger Grote, Senior Lecturer at Sahlgrenska Academy, University of Gothenburg.

In the present study, the researchers sought to see whether carbonic anhydrase (CA) inhibiting drugs could reduce sleep apnea. CA is an enzyme that regulates levels of carbonic acid and carbon dioxide in the body and is already used to treat glaucoma, epilepsy, and other disorders. 

For the current study, the researchers recruited 59 patients with moderate or severe sleep apnea. They were randomly assigned to receive either 400 mg or 200 mg of the CA inhibitor or a placebo. The study ran over four weeks. 

The researchers found that both doses of CA inhibition significantly reduced pauses in breathing. The 400mg group experienced a 41% decline in breathing pauses- from an average of 55.3 to 33.1, while the 200mg group experienced a 32.1% decline- from 61.2 to 40.7. 

The researchers further noted that none of the patients experienced serious adverse side effects; however, six patients in the 400mg group withdrew from the study due to adverse events. They also noted that side effects were rare, although more commonly experienced on the higher dose, and included headache and breathlessness. 

As CA inhibitors are already available on the market, the researchers say they may achieve approval for sleep apnea too relatively soon. They say, however, that before this, further research into their ability to treat the condition is needed. 

 

Sources: American Journal of Respiratory and Critical Care Medicine, Science Daily

 

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
MAY 13, 2022
Drug Discovery & Development
Multiple Mental Health Diagnoses are Increasingly Common. Why?
MAY 13, 2022
Multiple Mental Health Diagnoses are Increasingly Common. Why?
Mental illness has become increasingly common. The number of people with anxiety and depression, specifically, has stead ...
MAY 25, 2022
Cannabis Sciences
NYU Researchers Find CBD effectively Reduces Post Operative Pain
MAY 25, 2022
NYU Researchers Find CBD effectively Reduces Post Operative Pain
  An NYU research study found that a cannabidiol (CBD) tablet safely and effectively reduced post-operative pain. T ...
JUN 06, 2022
Immunology
Using Antibodies to Create Potent Cancer Treatments
JUN 06, 2022
Using Antibodies to Create Potent Cancer Treatments
Cancer can arise from a variety of aberrations that cause cells to divide uncontrollably, and form a tumor. The causes o ...
JUN 10, 2022
Drug Discovery & Development
The consequences of inappropriate antibiotic prescriptions in children
JUN 10, 2022
The consequences of inappropriate antibiotic prescriptions in children
The discovery of antibiotics in the early 1900’s was one of the most important discoveries in medical history. The ...
JUN 27, 2022
Drug Discovery & Development
Potential Gene Targets Identified for Treating Deafness
JUN 27, 2022
Potential Gene Targets Identified for Treating Deafness
Researchers have identified three mutations of the MINAR2 gene that are linked to deafness. They say that the mutations ...
JUL 01, 2022
Coronavirus
Nanobodies Could Protect Us From Every Variant
JUL 01, 2022
Nanobodies Could Protect Us From Every Variant
Immune reactive molecules called nanobodies, which are based on molecules found in llamas could offer robust protection ...
Loading Comments...